Authorized Use for Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved
or licensed by FDA, but has been authorized for emergency use by FDA, under
an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals
6 months through 11 years of age. The emergency use of this product is only
authorized for the duration of the declaration that circumstances exist justifying
the authorization of emergency use of the medical product under Section 564(b) (1)
of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For most recent Fact Sheets, please visit www.cvdvaccine-us.com
COVID-19 Vaccination Considerations During Pregnancy
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
22 August 2023
12:00 pm – 1:00 pm ET
24 August 2023
4:00 pm – 5:00 pm ET
Select COVID-19 Vaccine 2023-2024 Formula Updates From June 2023 VRBPAC and ACIP Meetings
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
11 July 2023
12:00 pm – 1:00 pm ET
13 July 2023
4:00 pm – 5:00 pm ET
Long COVID: An Evolving Understanding of Post COVID-19 Conditions
Jenny Boucher, PharmD, BCPS
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
6 June 2023
12:00 pm – 1:00 pm ET
8 June 2023
4:00 pm – 5:00 pm ET
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5): Authorization and Recommendation Updates
Elizabeth Thoburn, MPH
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
26 April 2023
12:00 pm – 1:00 pm EST
27 April 2023
4:00 pm – 5:00 pm EST
Select COVID-19 Vaccine Updates from February ACIP Meeting
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
22 March 2023
12:00 pm – 1:00 pm EST
23 March 2023
4:00 pm – 5:00 pm EST
COVID-19 Vaccination: Considerations for Pediatric Patients
Maria D. McColgan, MD, MSEd
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
27 February 2023
12:00 PM – 1:00 PM EST
28 February 2023
5:00 PM – 6:00 PM EST
01 March 2023
3:00 PM – 4:00 PM EST
Select Bivalent COVID-19 Vaccine Information Presented at Recent FDA Advisory Committee Meeting
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
13 February 2023
12:00 pm – 1:00 pm EST
14 February 2023
5:00 pm – 6:00 pm EST
15 February 2023
3:00 pm – 4:00 pm EST
Effectiveness of COVID-19 mRNA Vaccines, Bivalent (Original and Omicron BA.4/BA.5) Against Omicron Sublineages
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
11 January 2023
12:00 pm – 1:00 pm EST
12 January 2023
5:00 pm – 6:00 pm EST
17 January 2023
3:00 pm – 4:00 pm EST
Neutralization of Omicron Sublineages with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
13 December 2022
12:00 pm – 1:00 pm EST
14 December 2022
5:00 pm – 6:00 pm EST
15 December 2022
3:00 pm – 4:00 pm EST
COVID-19 and COVID-19 mRNA Vaccine-Related Myocarditis
Santiago Lopez, MD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
29 November 2022
12:00 pm –1:00 pm EST
01 December 2022
4:00 pm –5:00 pm EST
Medical Update on Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
14 November 2022
12:00 pm – 1:00 pm EST
15 November 2022
5:00 pm – 6:00 pm EST
16 November 2022
3:00 pm – 4:00 pm EST
